Variations in radioiodine ablation: decision-making after total thyroidectomy.

Area of Science:

• Endocrinology
• Nuclear Medicine
• Oncology

Background:

• The role of radioiodine treatment post-thyroidectomy for differentiated thyroid cancer (DTC) is evolving.
• Recent guideline revisions (ATA 2015 vs. EANM 2008) have introduced significant changes in treatment recommendations.
• Hypothesis: Marked variability exists in current radioiodine treatment regimens.

Purpose of the Study:

• To analyze decision-making in Swiss hospitals regarding radioiodine treatment for DTC.
• To map current practices and identify consensus and discrepancies in treatment protocols.
• To investigate variations in radioiodine remnant ablation (RRA) strategies.

Main Methods:

• Analysis of decision-making processes in all Swiss hospitals providing radioiodine treatment.
• Mapping of current community practices for DTC management.
• Identification of consensus and discrepancies in treatment protocols.

Main Results:

• For low-risk DTC patients, some centers offer only follow-up, while others recommend RIT with significant activities.
• Radioiodine treatment is generally recommended for intermediate- and high-risk DTC patients.
• Significant variations observed in dosing and preparation methods (recombinant human thyroid stimulation hormone vs. thyroid hormone withdrawal).

Conclusions:

• Current practices for radioiodine treatment in differentiated thyroid cancer show considerable variability.
• Discrepancies exist, particularly for low-risk patients, regarding the necessity and extent of radioiodine administration.
• Variability in preparation methods (rhTSH vs. THW) highlights differing institutional approaches.